Insiders · SGMO

Sandy Macrae

President, CEO and Director at Sangamo Therapeutics, Inc (SGMO)

Sandy Macrae has filed 22 insider reports with the SEC since January 2021, as president and CEO and Director at Sangamo Therapeutics, Inc (SGMO). The latest filing, on May 27, 2026, reports shares withheld for taxes or exercise price at Sangamo Therapeutics, Inc (SGMO).

Filings
22
Companies
1
Bought on market
None
Sold on market
None

Companies where Sandy Macrae is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Sangamo Therapeutics, Inc logo
SGMO
Sangamo Therapeutics, Inc
President, CEO and Director1,895,043May 27, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Sandy Macrae with

Other insiders at the same companies

Questions about Sandy Macrae

What is Sandy Macrae's role at Sangamo Therapeutics, Inc?
Sandy Macrae reports to the SEC as president and CEO and Director at Sangamo Therapeutics, Inc (SGMO), according to the latest filing on May 27, 2026.
How many shares does Sandy Macrae own?
After the latest filing that states it, Sandy Macrae directly owned 1,895,043 shares of Sangamo Therapeutics, Inc (SGMO). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Sandy Macrae bought or sold stock recently?
No open-market purchases or sales by Sandy Macrae are on file. The filings report shares withheld for taxes or exercise price and grant or award.
How do I get alerts when Sandy Macrae files?
Follow Sandy Macrae on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Sandy Macrae (SEC CIK 0001675687). Totals count each trade once, skipping amendments whose original is on file, from Jan 27, 2021 on. View on SEC EDGAR · Get this as JSON